Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| platelet-derived growth factor | 4925 | 165101-51-9 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A recombinant human platelet-derived growth factor B-chain dimer used to promote WOUND HEALING by stimulating PHYSIOLOGIC ANGIOGENESIS.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 16, 1997 | FDA | OMJ PHARMACEUTICALS |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Wound complication | 202.08 | 89.95 | 31 | 305 | 4732 | 90623379 |
| Toe amputation | 106.68 | 89.95 | 16 | 320 | 2053 | 90626058 |
| Osteomyelitis | 91.39 | 89.95 | 21 | 315 | 27825 | 90600286 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Wound complication | 261.33 | 70.87 | 42 | 466 | 2645 | 42618182 |
| Osteomyelitis | 165.17 | 70.87 | 39 | 469 | 18184 | 42602643 |
| Toe amputation | 107.45 | 70.87 | 20 | 488 | 2909 | 42617918 |
| Cellulitis | 82.91 | 70.87 | 30 | 478 | 61555 | 42559272 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Wound complication | 300.94 | 51.49 | 50 | 777 | 6127 | 110582345 |
| Osteomyelitis | 201.69 | 51.49 | 48 | 779 | 36552 | 110551920 |
| Toe amputation | 182.35 | 51.49 | 31 | 796 | 4307 | 110584165 |
| Cellulitis | 115.62 | 51.49 | 41 | 786 | 125975 | 110462497 |
| Application site infection | 95.20 | 51.49 | 11 | 816 | 84 | 110588388 |
| Wound infection staphylococcal | 74.46 | 51.49 | 14 | 813 | 3395 | 110585077 |
| Application site pain | 73.67 | 51.49 | 15 | 812 | 5484 | 110582988 |
| Inappropriate schedule of product administration | 52.55 | 51.49 | 27 | 800 | 203610 | 110384862 |
None
| Source | Code | Description |
|---|---|---|
| ATC | A01AD08 | ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Other agents for local oral treatment |
| ATC | D03AX06 | DERMATOLOGICALS PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS CICATRIZANTS Other cicatrizants |
| FDA CS | M0017024 | Platelet-Derived Growth Factor |
| MeSH PA | D000925 | Anticoagulants |
| MeSH PA | D006133 | Growth Substances |
| MeSH PA | D006401 | Hematologic Agents |
| MeSH PA | D043925 | Angiogenesis Inducing Agents |
| FDA EPC | N0000175885 | Human Platelet-derived Growth Factor |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Neuropathic diabetic ulcer - foot | indication | 201251005 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Platelet-derived growth factor receptor | Kinase | AGONIST | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| D03065 | KEGG_DRUG |
| 4021101 | VUID |
| N0000148557 | NUI |
| 4021101 | VANDF |
| CHEBI:749433 | CHEBI |
| CHEMBL1201556 | ChEMBL_ID |
| DB00102 | DRUGBANK_ID |
| 115238 | RXNORM |
| 11521 | MMSL |
| 4248 | MMSL |
| 007329 | NDDF |
| 108936003 | SNOMEDCT_US |
| 386940001 | SNOMEDCT_US |
| C0379135 | UMLSCUI |
| D000077214 | MESH_DESCRIPTOR_UI |
| 7454 | INN_ID |
| 1B56C968OA | UNII |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Regranex Gel 0.01% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 85822-734 | GEL | 0.10 mg | TOPICAL | BLA | 20 sections |